about
Mefloquine for preventing malaria in pregnant womenUnfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patientsSafety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trialA phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsThe cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan AfricaIntermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trialReduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control studyIntermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trialIntermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trialEconomic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancyMortality, Morbidity, and Developmental Outcomes in Infants Born to Women Who Received Either Mefloquine or Sulfadoxine-Pyrimethamine as Intermittent Preventive Treatment of Malaria in Pregnancy: A Cohort StudyImpact of the Mass Drug Administration for malaria in response to the Ebola outbreak in Sierra LeoneHIV Incidence and Spatial Clustering in a Rural Area of Southern MozambiqueThe role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trialSafety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trialArterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialImmunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialRTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.Levels and trends of demographic indices in southern rural Mozambique: evidence from demographic surveillance in Manhiça districtAge interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation.A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic.A 10 year study of the cause of death in children under 15 years in Manhiça, Mozambique.Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.Malaria prevention with IPTp during pregnancy reduces neonatal mortalityEffects of HIV infection on maternal and neonatal health in southern Mozambique: A prospective cohort study after a decade of antiretroviral drugs roll out.Resisting and tolerating P. falciparum in pregnancy under different malaria transmission intensitiesIntermittent preventive treatment with sulfadoxine-pyrimethamine does not modify plasma cytokines and chemokines or intracellular cytokine responses to Plasmodium falciparum in Mozambican children.Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia.Performance of multiplex commercial kits to quantify cytokine and chemokine responses in culture supernatants from Plasmodium falciparum stimulations.Spatio-temporal analysis of mortality among children under the age of five in Manhiça (Mozambique) during the period 1997-2005.Impact of malaria at the end of pregnancy on infant mortality and morbidity.RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites.Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children.Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigensThe epidemiology of malaria in adults in a rural area of southern MozambiqueAge-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children.Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial.Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates
P50
Q24186956-0CA64289-1DE1-4460-B0A2-6421C36F69D5Q28193517-27917364-E3EB-4934-BE5D-CA175478570AQ28254031-B52C06D1-37BD-4DE5-9DF9-E96F6423CE34Q28278852-B7839BA8-04D1-4750-B18C-12D10FDDD4CCQ28474404-66022E0B-5757-4D98-9896-A456B5A1B5AEQ28481649-7CBE2651-435A-4C1E-820E-AD0F43BC7586Q28483318-6B0B758A-3279-481D-A332-3B5799AE31A9Q28543146-30B3ACB5-715A-474E-BC8F-4026FB3CB296Q28543154-70D3E41D-2198-4105-93CA-D30471EB833EQ28546725-05EB1231-C40B-4F19-9AA5-BD1FF873F254Q28550346-3E8BA670-2BBD-4921-8093-6B2980AD7994Q28595536-AC8A0CAE-7C32-4234-BDFB-3A778F7EBEAAQ28647478-699F3D14-38F8-4419-AC88-FD911A56F676Q28731458-1684F222-97EE-469F-B8E2-104C7974689AQ28748565-2AA32499-3BD2-4ED3-ADAB-52B8FC190BD0Q29617955-62B4ECAA-9C5A-4F4B-8833-3DADF2DFDBE1Q30991737-77C424D5-4BC1-4CEB-91BF-C9392D4EE7CBQ33251913-24D2FE09-9D31-4316-A30C-C5DE7C67DDAFQ33265108-2FC95FB7-04BC-4A6E-87E1-A9BA33A7B0CAQ33293164-870F4D21-E17E-4740-B591-1CA65438AB32Q33327356-F734A166-EFC7-4F64-8E8B-4250F7E7EB1DQ33411580-6BF159E9-8A3C-4928-BEA7-72C950B96977Q33430011-2F327BDC-A5B5-44F3-8D0E-5755875A2438Q33535850-05C828CF-0676-486F-8FE5-498B9F99E559Q33757461-FF173C4E-3626-4175-BAA7-1C9CED578FCEQ33910163-9D558DC0-CA6A-4260-8EE5-BD12F9B5868FQ34142179-732F14B0-8326-40DD-A10B-16A6F96761BBQ34359432-A766C80A-A6FC-41C1-8E49-F21D7379A857Q34487139-B314072E-B53B-472F-AB87-DBA99F174F55Q34527838-AFCBFCA2-19FD-4068-AAB8-3A8530DE888FQ34542147-AFA91CDD-4B7C-4739-8FA6-5C1463A87165Q34632807-BD2806C4-863B-470F-BB9B-2AF1E14A25E9Q34764578-41379154-3E89-43AD-8F1C-642D0982072FQ35148353-A1A44382-C0B9-46B4-8784-1D25B4CC9DBEQ35198729-15AE0E6C-0668-4BDC-AA56-E9A472890177Q35330733-F6804D40-C9B1-4214-8789-845B1E3E7341Q35633231-274BD305-DBD3-4124-A219-74C9E4EE8802Q35739071-2CA75DD3-4548-4EFC-BE17-5DF458E46F0FQ35742175-132663DC-A126-4540-9C1D-98F3348E4FDBQ35922955-2BDB32CA-E2E4-4147-8C18-3A1D9B5640A7
P50
name
John J Aponte
@en
type
label
John J Aponte
@en
prefLabel
John J Aponte
@en